{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T09:16:44Z","timestamp":1768814204532,"version":"3.49.0"},"reference-count":12,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2015,4,28]],"date-time":"2015-04-28T00:00:00Z","timestamp":1430179200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100001698","name":"Israel Cancer Research Fund","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100001698","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100002597","name":"American Physicians Fellowship for Medicine in Israel","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100002597","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003975","name":"Israel Cancer Association","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003975","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100005005","name":"Ben-Gurion University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005005","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["obgyn.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acta Obstet Gynecol Scand"],"published-print":{"date-parts":[[2015,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We conducted a proof of concept study evaluating prolonged treatment with pegylated liposomal doxorubicin for recurrent ovarian, tubal and peritoneal carcinoma. Thirteen consecutive patients received an average of 22.6 cycles of pegylated liposomal doxorubicin, with an average cumulative dose of 1409\u00a0mg\/m<jats:sup>2<\/jats:sup>. Progression\u2010free survival at 18\u00a0months was 61.5%, and was longer than the previous progression\u2010free survival in 10 of the 13 patients. Overall 5\u2010year survival was 78.8%. Despite prolonged use and relatively large cumulative doses of pegylated liposomal doxorubicin, most of the patients had mild to moderate side\u2010effects, none of the patients had detectable cardio\u2010toxic side\u2010effects, and a positive impact on the performance status was noticed. Thus, in our group of patients, continued pegylated liposomal doxorubicin treatment was associated with a longer progression\u2010free interval and allowed improved performance status with manageable toxicity.<\/jats:p>","DOI":"10.1111\/aogs.12642","type":"journal-article","created":{"date-parts":[[2015,4,3]],"date-time":"2015-04-03T18:42:38Z","timestamp":1428086558000},"page":"776-780","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Prolonged pegylated liposomal doxorubicin treatment for recurrent pelvic cancers: a feasibility study"],"prefix":"10.1111","volume":"94","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8712-9197","authenticated-orcid":false,"given":"Alex","family":"Rabinovich","sequence":"first","affiliation":[{"name":"Division of Gynecologic Oncology Segal Cancer Center Jewish General Hospital Lady Davis Research Institute Montreal Quebec Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnihotram V.","family":"Ramanakumar","sequence":"additional","affiliation":[{"name":"Division of Cancer Epidemiology Department of Oncology McGill University Montreal Quebec Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susie","family":"Lau","sequence":"additional","affiliation":[{"name":"Division of Gynecologic Oncology Segal Cancer Center Jewish General Hospital Lady Davis Research Institute Montreal Quebec Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walter H.","family":"Gotlieb","sequence":"additional","affiliation":[{"name":"Division of Gynecologic Oncology Segal Cancer Center Jewish General Hospital Lady Davis Research Institute Montreal Quebec Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,4,28]]},"reference":[{"key":"e_1_2_7_2_1","first-page":"CD007414","article-title":"Maintenance chemotherapy for ovarian cancer","volume":"6","author":"Mei L","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_7_3_1","first-page":"288","article-title":"Recurrent epithelial ovarian cancer: an update on treatment","volume":"27","author":"Foley OW","year":"2013","journal-title":"Oncology"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2013.05.029"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2013.5"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/GRF.0b013e31824b9bc5"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/898146"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2012.05.028"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl484"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2013.03.012"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2014.03.565"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.51.4489"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70244-X"}],"container-title":["Acta Obstetricia et Gynecologica Scandinavica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Faogs.12642","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Faogs.12642","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/aogs.12642","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T11:02:07Z","timestamp":1695553327000},"score":1,"resource":{"primary":{"URL":"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/10.1111\/aogs.12642"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,28]]},"references-count":12,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["10.1111\/aogs.12642"],"URL":"https:\/\/doi.org\/10.1111\/aogs.12642","archive":["Portico"],"relation":{},"ISSN":["0001-6349","1600-0412"],"issn-type":[{"value":"0001-6349","type":"print"},{"value":"1600-0412","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,28]]},"assertion":[{"value":"2015-01-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-03-30","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-04-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}